<DOC>
	<DOCNO>NCT01381289</DOCNO>
	<brief_summary>The purpose expand access program provide VX-770 prior commercial availability people cystic fibrosis ( CF ) least one copy G551D-CFTR mutation critical medical need eligible participation Vertex-sponsored study .</brief_summary>
	<brief_title>VX-770 Expanded Access Program</brief_title>
	<detailed_description>VX-770 , compound develop Vertex Pharmaceuticals Incorporated ( Vertex ) treatment CF , orally bioavailable small molecule target underlie defect CF , dysfunctional CFTR protein . In Phase 3 study VX-770 patient CF G551D CFTR mutation , improvement CFTR function ( measure reduction sweat chloride concentration ) improvement lung function observe . Patients interested VX-770 Expanded Access contact CF physician participation . Physicians interested participate site contact 800-745-4484 .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female confirm diagnosis CF , sweat chloride &gt; 60 mmol/L OR 2 CFcausing mutation AND chronic sinopulmonary disease OR gastrointestinal/nutritional abnormality . Have G551DCFTR mutation least 1 allele Will age 6 year old date sign informed consent form Highest FEV1 6 month prior screen ≤ 40 % predict value patient document active lung transplant wait list If female , currently pregnant Abnormal liver function , screen recent clinical laboratory testing , define &gt; 3 × upper limit normal ( ULN ) , 3 following : AST , ALT , GGT , serum alkaline phosphatase , total bilirubin Is currently require invasive mechanical ventilation Is currently participate , participate past 30 day another therapeutic clinical study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>